6061 studies found for:    "breast cancer"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
2 Completed Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment according to standards fpr triple negative and Her2pos breast cancer patients
3 Active, not recruiting Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel;   Drug: Paclitaxel
4 Recruiting GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
5 Active, not recruiting Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer;   Stage IV Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: Abraxane;   Drug: Tigatuzumab
6 Active, not recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod;   Other: laboratory biomarker analysis
7 Terminated Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Conditions: Breast Cancer;   HER2 Positive Breast Cancer;   Metastatic Breast Cancer;   Cancer of the Breast
Interventions: Drug: IPI-504;   Drug: Trastuzumab
8 Active, not recruiting Capecitabine in Women With Operable Breast Cancer
Conditions: Invasive Breast Carcinoma;   Primary Invasive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Intervention: Drug: Capecitabine
9 Active, not recruiting Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Conditions: HER2-Negative Breast Cancer;   Triple Negative Breast Cancer;   Breast Cancer;   Cancer of Breast;   Breast Tumors
Interventions: Drug: E7389 (Eribulin Mesylate);   Drug: Vinorelbine injection
10 Not yet recruiting Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Lobular Breast Carcinoma in Situ;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: accelerated partial breast irradiation;   Radiation: intensity-modulated radiation therapy;   Radiation: image-guided radiation therapy;   Procedure: therapeutic conventional surgery;   Other: questionnaire administration;   Other: laboratory biomarker analysis
11 Active, not recruiting Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Lobular Breast Carcinoma in Situ;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer
Interventions: Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Genetic: gene expression analysis;   Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: aromatase inhibition therapy
12 Recruiting A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
Conditions: Taxane-induced Peripheral Neuropathy;   Chemotherapy-induced Peripheral Neuropathy (CIPN);   Early-Stage Breast Carcinoma;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Procedure: Immediate Acupuncture Group;   Procedure: Delayed Acupuncture Group
13 Completed A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
Conditions: Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer;   Breast Cancer;   Locally Advanced
Intervention: Drug: gemcitabine, epirubicin, paclitaxel
14 Active, not recruiting Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Skin Metastases;   Stage IV Breast Cancer
Interventions: Drug: imiquimod;   Drug: Abraxane;   Other: laboratory biomarker analysis;   Genetic: RNA analysis;   Other: immunoenzyme technique
15 Active, not recruiting Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: AZD2281;   Drug: Paclitaxel
16 Withdrawn Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
Conditions: Breast Cancer;   Metastatic Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Ixabepilone;   Drug: Capecitabine;   Drug: Motesanib
17 Completed Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer
Conditions: Breast Cancer;   Estrogen Receptor-Positive Breast Cancer;   Breast Cancer, Estrogen Receptor-Positive;   ER+ Breast Cancer
Interventions: Drug: entinostat;   Drug: exemestane
18 Active, not recruiting MUC1 Vaccine for Triple-negative Breast Cancer
Conditions: Breast Cancer;   Inflammatory Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Biological: MUC-1 peptide vaccine;   Biological: poly ICLC;   Biological: MUC1 peptide-poly-ICLC adjuvant vaccine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry
19 Completed Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
Conditions: Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Capecitabine
20 Terminated Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast Cancer
Conditions: Depression;   Stage I Breast Cancer;   Stage IIIA Breast Cancer;   Nutrition;   Stage II Breast Cancer;   Psychosocial Effects/Treatment;   Quality of Life
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years